Vicore Pharma Holding AB (OSTO:VICO BTA) Total Liabilities : kr63.08 Mil (As of Mar. 2025)

View and export this data going back to . Start your Free Trial

What is Vicore Pharma Holding AB Total Liabilities?

Vicore Pharma Holding AB's Total Liabilities for the quarter that ended in Mar. 2025 was kr63.08 Mil.

Vicore Pharma Holding AB's quarterly Total Liabilities increased from Sep. 2024 (kr29.17 Mil) to Dec. 2024 (kr73.78 Mil) but then declined from Dec. 2024 (kr73.78 Mil) to Mar. 2025 (kr63.08 Mil).

Vicore Pharma Holding AB's annual Total Liabilities declined from Dec. 2022 (kr48.92 Mil) to Dec. 2023 (kr42.45 Mil) but then increased from Dec. 2023 (kr42.45 Mil) to Dec. 2024 (kr73.78 Mil).

Vicore Pharma Holding AB Total Liabilities Historical Data

The historical data trend for Vicore Pharma Holding AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vicore Pharma Holding AB Total Liabilities Chart

Vicore Pharma Holding AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

52.00

67.85

48.92

42.45

73.78

Vicore Pharma Holding AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Liabilities	Get a 7-Day Free Trial															51.83	43.75	29.17	73.78	63.08

Vicore Pharma Holding AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Vicore Pharma Holding AB's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	72.908	+	(0	+	0.871
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	73.78

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	1203.108	-	1129.329
	=	73.78

Vicore Pharma Holding AB's Total Liabilities for the quarter that ended in Mar. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	62.091	+	(0	+	0.987
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	63.08

Total Liabilities	=	Total Assets (Q: Mar. 2025 )	-	Total Equity (Q: Mar. 2025 )
	=	1083.333	-	1020.255
	=	63.08

Vicore Pharma Holding AB Total Liabilities Related Terms

Thank you for viewing the detailed overview of Vicore Pharma Holding AB's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Vicore Pharma Holding AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicore Pharma Holding AB (OSTO:VICO BTA) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

VICO:Sweden

Address

Kornhamnstorg 53, Stockholm, SWE, 111 27

Website

https://www.vicorepharma.com

Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2b development for IPF. The company also has an investigational medical device in clinical development, namely, Almee, which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.

Vicore Pharma Holding AB Headlines

No Headlines